Hormone Therapy for Women: How Estrogen and Progesterone Combination Therapy Works

More than one million American women enter menopause every year, yet surveys consistently show that fewer than 30% of those experiencing moderate-to-severe symptoms ever receive treatment. That gap between suffering and solution is closing — partly because the science behind hormone therapy for women has advanced significantly, and partly because regulators are finally catching up with the evidence.

In February 2026, the FDA approved labeling changes for six major menopausal hormone therapy products, removing outdated warnings about cardiovascular disease, breast cancer, and probable dementia that had discouraged millions of women from seeking relief for more than two decades. Comprehending how estrogen and progesterone work together — and why that combination matters — puts you in a much stronger position to have an informed conversation with your doctor.

Start treatment with hormone therapy for women in Brooklyn.

Key Takeaways

• Combination hormone therapy pairs estrogen with progesterone (or a progestin) to relieve menopausal symptoms while protecting the uterine lining.
• In February 2026, the FDA removed overstated risk warnings from six hormone therapy products, reflecting updated scientific evidence.
• Not every woman needs the same formulation — dosage, delivery method, and hormone type are individualized based on health history.
• Women with an intact uterus generally require progesterone alongside estrogen to prevent endometrial overgrowth.
• Consulting a qualified endocrinologist or primary care provider is the essential first step before starting any hormonal regimen.

What Estrogen and Progesterone Actually Do in the Body

To understand combination therapy, it helps to know what each hormone does on its own.

Estrogen is the primary female sex hormone. It regulates the menstrual cycle, maintains bone density, supports cardiovascular function, and keeps vaginal and urinary tissues healthy. When estrogen levels drop during perimenopause and menopause, women often experience hot flashes, night sweats, vaginal dryness, sleep disruption, and mood changes.

Progesterone is produced mainly in the ovaries after ovulation. Its most critical role in hormone therapy is protecting the endometrium — the lining of the uterus. Estrogen alone stimulates the uterine lining to grow. Without progesterone to balance that growth, the lining can thicken abnormally, a condition called endometrial hyperplasia, which raises the risk of uterine cancer. Progesterone signals the lining to shed or stabilize, keeping that growth in check.

When a woman still has her uterus, combination therapy — estrogen plus progesterone or a synthetic progestin — is the standard of care. Women who have had a hysterectomy typically use estrogen alone.

The Difference Between Progesterone and Progestins

These terms are often used interchangeably, but they are not the same thing:

Term	What It Is	Common Examples
Progesterone	Bioidentical hormone identical to what the body makes	Prometrium (oral micronized)
Progestin	Synthetic compound that mimics progesterone	Medroxyprogesterone acetate (MPA)
Dydrogesterone	Semi-synthetic, structurally close to natural progesterone	Femoston (combined tablet)

Research published in May 2026 found that women using an estradiol-dydrogesterone combination experienced significantly greater reductions in menopausal symptom scores compared to those using dydrogesterone alone — with clinical response rates of 51.2% versus 31.5%, respectively. That kind of data reinforces why the combination approach is often more effective than single-hormone treatment.

How Combination Hormone Therapy for Women Is Structured

There is no single “combination therapy” — it is a category of treatment with several distinct protocols. Your provider will choose based on your symptoms, your uterine status, your age, and how far along you are in the menopausal transition.

Sequential (Cyclical) Therapy

In sequential therapy, estrogen is taken every day. Progesterone is added for a set number of days each month — typically 12 to 14 days. This mimics the natural hormonal rhythm of the menstrual cycle and usually produces a monthly withdrawal bleed, which many perimenopausal women find familiar and reassuring.

In May 2026, the British Menopause Society updated its clinical guidelines to recommend higher doses of oral micronized progesterone for women on higher estrogen doses in sequential regimens — increasing from 200 mg to 300 mg for 12 days per month. This reflects growing recognition that endometrial protection must scale with estrogen dose.

Continuous Combined Therapy

In continuous combined therapy, both estrogen and progesterone are taken every day without a break. The goal is to prevent any monthly bleed, making it a preferred option for postmenopausal women who have not had a period for at least one year. The British Menopause Society’s 2026 update also recommended increasing continuous progesterone from 100 mg to 200 mg daily when higher estrogen doses are used.

Delivery Methods

Combination therapy is not limited to pills. Options include:

• Oral tablets or capsules — convenient and well-studied
• Transdermal patches — deliver hormones through the skin, bypassing first-pass liver metabolism
• Topical gels or creams — applied to the skin daily
• Vaginal rings — primarily address local urogenital symptoms
• Combination patches — contain both estrogen and progestin in one patch

The delivery method affects how the hormones are absorbed and metabolized, which can influence both effectiveness and side effect profiles. Transdermal estrogen, for example, carries a lower risk of blood clots compared to oral estrogen because it does not pass through the liver.

The 2026 Regulatory Shift: What Changed and Why It Matters

For over 20 years, hormone therapy products carried prominent “black box” warnings — the FDA’s strongest safety alert — linking them to serious risks including heart disease, stroke, blood clots, breast cancer, and dementia. These warnings stemmed largely from the Women’s Health Initiative (WHI) study published in 2002, which studied a specific oral progestin combination in a population of older postmenopausal women.

Subsequent research showed that the WHI findings were misapplied to all women of all ages using all types of hormone therapy. The risks were substantially different — and often much lower — for younger women in early menopause using modern formulations.

In November 2025, the FDA began a comprehensive review of hormone therapy labeling. By February 2026, the agency approved updated labels for six products — including Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva — removing the cardiovascular disease, breast cancer, and probable dementia warnings from their boxed labels. New labeling is being written to provide age-specific guidance rather than blanket warnings.

This shift does not mean hormone therapy is risk-free. It means the conversation between patient and provider can now be grounded in current science rather than outdated fear.

Who Is a Good Candidate for Combination Hormone Therapy for Women?

Combination hormone therapy is generally most appropriate for:

• Women in perimenopause or early postmenopause (typically under age 60, or within 10 years of their last period) with moderate-to-severe symptoms
• Women who have an intact uterus and need progesterone for endometrial protection
• Women whose quality of life is significantly affected by hot flashes, sleep disruption, mood changes, or vaginal symptoms
• Women at elevated risk for osteoporosis who may benefit from estrogen’s bone-protective effects

It may not be appropriate for women with a personal history of certain cancers, unexplained vaginal bleeding, active liver disease, or a history of blood clots. A thorough medical evaluation is essential before starting treatment.

If you have noticed changes in your energy, mood, sleep, or menstrual patterns that concern you, learning when to see an endocrinologist for hormonal issues is a helpful first step.

Monitoring and Adjusting Hormone Therapy Over Time

Starting combination therapy is not a set-it-and-forget-it decision. Ongoing monitoring is essential to ensure the treatment remains safe and effective as your body changes.

Regular follow-up typically includes:

• Symptom review — Are hot flashes, sleep, and mood improving?
• Endometrial assessment — Especially if unexpected bleeding occurs
• Blood pressure and cardiovascular markers — Hormones can affect these values
• Bone density scans — Particularly for women at osteoporosis risk
• Breast health — Routine mammography per standard guidelines

If you are managing other hormonal conditions alongside menopause, such as thyroid disorders or diabetes, coordinated care becomes even more important. Comprehending how often a diabetic should see an endocrinologist gives useful context for how chronic hormonal conditions require consistent specialist oversight.

Our endocrinology team in Brooklyn works closely with primary care providers to ensure that hormone therapy fits within a woman’s complete health picture — not just her menopause symptoms.

Hormone Therapy for Women and Related Health Considerations

Menopause does not happen in isolation. Many women entering this life stage are also managing cardiovascular health, bone density concerns, mental wellness, and other conditions that intersect with hormonal changes.

Heart health: Estrogen has a known cardioprotective effect in younger women. The timing of hormone therapy initiation — starting closer to the onset of menopause rather than years later — appears to matter significantly for cardiovascular outcomes. Our heart care services in Brooklyn can help assess cardiovascular risk as part of a comprehensive menopause evaluation.

Mental health: Hormonal fluctuations during perimenopause are closely linked to anxiety, depression, and cognitive changes. If mood symptoms are prominent, a coordinated approach involving both hormone management and mental health support may be most effective. Our psychiatry and mental health services are available for women navigating this transition.

Thyroid function: Thyroid disorders are more common in women and can produce symptoms that overlap significantly with menopause — fatigue, weight changes, mood shifts, and sleep problems. If you are unsure whether your symptoms are hormonal or thyroid-related, reading about when a woman should see an endocrinologist can help clarify the next step.

Primary care coordination: For many women, the primary care physician is the first point of contact for menopausal concerns. Our primary care providers in Brooklyn are experienced in recognizing when specialist referral is appropriate and in managing the broader health picture alongside hormonal treatment.

FAQs:

Do I need progesterone if I have had a hysterectomy?

Generally, no. Progesterone’s primary role in combination therapy is to protect the uterine lining from the stimulating effects of estrogen. Women who have had a complete hysterectomy no longer have a uterus to protect, so they typically use estrogen-only therapy. Nevertheless, every situation is individual, and your provider will confirm the appropriate regimen based on your surgical history and overall health.

How long does it take for combination hormone therapy to work?

Most women notice improvement in hot flashes and sleep within two to four weeks of starting therapy. Vaginal symptoms may take a bit longer — often six to twelve weeks — to fully respond. Mood and cognitive symptoms can also improve gradually over the first few months. If you are not experiencing meaningful relief after three months, your provider may adjust the dose or delivery method.

Is combination hormone therapy safe for long-term use?

The answer depends on the individual. Current evidence, including the updated FDA labeling from February 2026, supports the use of hormone therapy at the lowest effective dose for as long as it is needed to manage symptoms. For women who start therapy in early menopause and are in good health, the benefit-risk balance is generally favorable. Annual reviews with your provider help ensure the therapy remains appropriate over time.

Can I use hormone therapy if I have a family history of breast cancer?

A family history of breast cancer is an important factor in the conversation, but it does not automatically rule out hormone therapy. The type of therapy, the specific hormones used, and the duration all influence risk. Bioidentical progesterone, for example, appears to carry a more favorable breast safety profile than some synthetic progestins. This is a nuanced discussion that requires a thorough evaluation by a qualified physician who knows your complete medical and family history.

References

• The Menopause Society (formerly NAMS). (2022). The 2022 Hormone Therapy Position Statement of The Menopause Society. Menopause, 29(7), 767–794. https://doi.org/10.1097/GME.0000000000002028
• Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2022). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975–4011. https://doi.org/10.1210/jc.2015-2236
• National Institute on Aging. (2022). Menopause. U.S. Department of Health and Human Services. https://www.nia.nih.gov/health/menopause
• Manson, J. E., & Kaunitz, A. M. (2021). Menopause management — Getting clinical care back on track. New England Journal of Medicine, 374(9), 803–806. https://doi.org/10.1056/NEJMp1514242